Platinum(II) complexes such as cisplatin, carboplatin and oxaliplatin are clinically approved for the therapy of various solid tumors. Challenging pathogenic properties of cancer cells and the response of cancers towards platinum-based drugs are strongly influenced by non-coding small RNA molecules, the microRNAs (miRNAs). Both increased platinum activity and formation of tumor resistance towards platinum drugs are controlled by miRNAs. This review gives an overview of the interactions between platinum-based drugs and miRNAs, and their influence on platinum activity in various cancer types is discussed.
Keywords: 5-FU, 5-fluorouracil; Anticancer drugs; CBDCA, cyclobutane-1,1-dicarboxylate; Carboplatin; Cisplatin; DACH, 1,2-diaminocyclohexane; DDP, cisplatin; EGCG, (−)-epigallocatechin-3-gallate; EOX, epirubicin/oxaliplatin/xeloda; FOLFOX, folinate/5-FU/oxaliplatin; GC, gemcitabine/cisplatin, gastric cancer; LNA, locked nucleic acid; MVAC, methotrexate/vinblastine/adriamycin/cisplatin; MicroRNA; Oxaliplatin; Platinum complexes; XELOX, xeloda/oxaliplatin; dTTP, deoxythymidine triphosphate.